SGEN Add to watchlist $228.74 0.16 (-0.07%) Last updated: Apr 16, 2026 02:30
52-Week Range
$228.74
$182.99 $228.74 $274.49

Fundamentals Overview

Seagen Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/B 15.07 P/S 21.99

Risk (Beta)

0.32 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 36% confidence Risk: Lower Volatility — Beta 0.32. Diversify and only invest what you can afford to lose.

Pressures (Sell):

Sentiment weakening (14 downgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$43.15B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$182.99 - $274.49
Volume vs Avg
N/A
Beta
0.32

About

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanc...
Sector: Healthcare
Headquarters: US
Employees: 3,256
IPO Date: Mar 2001
Beta: 0.32 (Less volatile than market)

Ratings & Grades at a Glance

Recent institutional grades: majority downgrades. Current institutional positions: Equal Weight: 6, Hold: 10, In Line: 2, Market Perform: 8, Outperform: 4.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 15.07
P/S (TTM) 21.99
Liquidity & enterprise
Current Ratio (TTM) 2.12
Quick Ratio (TTM) 1.6
Cash Ratio (TTM) 0.39
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -31.1%
Gross margin (TTM) 79.1%
Operating margin (TTM) -31.24%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for SGEN.

Analyst Sentiment at a Glance

Sentiment Weakening
Equal Weight 6Hold 10In Line 2Market Perform 8Outperform 4
0 upgrades, 14 downgrades
Price Target Consensus
Current $228.74
Median $170.00
Consensus $171.82
Low consensus $120.00
High consensus $222.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Truist Securities maintain Hold Hold 2023-10-18
Truist Securities maintain Hold Hold 2023-10-17
Truist Securities maintain Hold Hold 2023-09-25
Truist Securities maintain Hold Hold 2023-09-24
Morgan Stanley maintain Equal Weight Equal Weight 2023-08-03
Morgan Stanley maintain Equal Weight Equal Weight 2023-08-02
Berenberg downgrade Buy Hold 2023-03-24
Berenberg downgrade Buy Hold 2023-03-23
TD Securities maintain Market Perform Market Perform 2023-03-21
Truist Securities maintain Hold Hold 2023-03-20
TD Securities maintain Market Perform Market Perform 2023-03-20
Truist Securities maintain Hold Hold 2023-03-19
Morgan Stanley downgrade Overweight Equal Weight 2023-03-15
Raymond James downgrade Strong Buy Market Perform 2023-03-14
Barclays maintain Equal Weight Equal Weight 2023-03-14
Needham downgrade Buy Hold 2023-03-14
BMO Capital downgrade Outperform Market Perform 2023-03-14
Oppenheimer maintain Outperform Outperform 2023-03-14
JMP Securities downgrade Market Outperform Market Perform 2023-03-14
Morgan Stanley downgrade Overweight Equal Weight 2023-03-14
RBC Capital maintain Outperform Outperform 2023-03-14
Evercore ISI Group downgrade Outperform In Line 2023-03-13
RBC Capital maintain Outperform Outperform 2023-03-13
JMP Securities downgrade Market Outperform Market Perform 2023-03-13
Raymond James downgrade Strong Buy Market Perform 2023-03-13
Needham downgrade Buy Hold 2023-03-13
Oppenheimer maintain Outperform Outperform 2023-03-13
Barclays maintain Equal Weight Equal Weight 2023-03-13
BMO Capital downgrade Outperform Market Perform 2023-03-13
Evercore ISI Group downgrade Outperform In Line 2023-03-12